127 results about "Tumor type" patented technology

A nucleic acid probe or a novel set of such probes in a microarray is provided. The probe or probe set is useful in the prognosis of patients with clear cell renal cell carcinoma (CC-RCC), wherein aggressive and non-agressive CC-RCC tumor types are characterized by differential expression profiles of genes that hybridize with one or more of these probes. Microarrays and kits

The present disclosure provides methods for classifying ovarian tumors into BRCA1-type, BRCA2-type or non-BRCA-type tumor types by measuring expression levels of a plurality of disclosed ovarian tumor markers. The markers disclosed herein are useful in the diagnosis, staging, detection, and / or treatment of ovarian cancer. Also provided are methods of selecting a treatment regimen by selecting the tumor type. Ovarian cancer-linked logarithmic expression ratios and kits for diagnosis, staging, and detection of ovarian cancer using are also provided.

The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease.

The present invention discloses an informational computation method for classifying objects Specifically, the invention is a system, method, and computer-readable media for classifying tumors using a nonparametric statistical classifier in conjunction with an artificial neural network. The invention classifies unknown tumor types based on the correlation of unknown tumor's genetic expression compared to the genetic expression of know tumor types by first performing a nonparametric statistical analysis on the know data, training a artificial neural network with the known data, and then inputting the unknown tumor data into the neural network to calculate the probability that the sample tumor is a member of a class of tumors. By using a statistical classifier in conjunction with a neural network, the invention classifies unknown tumors more accurately then conventionally possible. Advantageously, by using a variety of tumor genetic expression data sets, including both published data sets and generated data sets, a tumor classifier, robust and accurate enough for clinical application, is provided.

The invention provides a methylated tumor marker STAMP-EP1 and application thereof and belongs to the field of molecular biology. The invention provides application of the methylated tumor marker STAMP-EP1 in preparation of tumor diagnosis reagents. The tumor marker STAMP-EP1 provided by the invention is hypermethylated in all tumor types, is hypomethylated in corresponding normal tissues, and hasvery high sensibility and specificity. A primer for detecting the STAMP-EP1 can be used for preparing a tumor diagnosis kit.

The present invention describes methods of identifying, detecting, imaging, isolating and locating cancer cells in a subject. The method invokes the use of near-infrared (NIR) organic carbocyanine dyes, particularly, near infrared heptamethine cyanine dyes and the detection of the fluorescence of these NIR dyes. The uptake of these dyes by cancer cells and not by normal cells, as well as their high intensity, among other things, allow for the detection of cancerous cells in a subject and facilitate their subsequent isolation. Further, detection of many tumor types and tumor cell populations under cell culture and in vivo conditions are described.

The invention discloses a methylation marker for early diagnosis of tumors. The marker comprises CpG islands corresponding to 248 probes in a HumanMethylation450BeadChip Kit and can well separate tumor tissue of the tumors in a training set from pericarcinomatous normal tissue. According to the methylation marker, a machine learning model constructed by adopting the methylation level of the markercan not only be used for clinically predicting the risk of 12 tumors in the training set, but also be applied to other tumors, and has good performance in the other tumors, and the area under the curve reaches 0.94; and it is proved that the methylation level of the screened CpG islands can be used for early diagnosis of almost all TCGA tumors. The invention further provides application of the CpG islands corresponding to 515 methylation markers in the HumanMethylation450BeadChip Kit in classification of the tumors and identification of tumor types.

Methods and pharmaceuticals for inhibiting or preventing metastasis formation in animals, including humans, having primary tumors, through the administration of phosphorothioates including their thiol and disulfide metabolites are disclosed. These compounds stimulate angiostatin levels, inhibit matrix metalloproteinases (MMPs), and stimulate manganese superoxidase dismutase (MnSOD). Phosphorothioates, of which amifostine is an example, can be administered as a combination therapy with traditional cancer therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy and gene-therapy. Inhibition or prevention of metastasis by phosphorothioates is independent of tumor type, including adenocarcinomas and sarcomas.

Here the inventors describe a tumor classifier based on protein expression. Also disclosed is the use of proteomics to construct a highly accurate artificial neural network (ANN)-based classifier for the detection of an individual tumor type, as well as distinguishing between six common tumor types in an unknown primary diagnosis setting. Discriminating sets of proteins are also identified and are used as biomarkers for six carcinomas. A leave-one-out cross validation (LOOCV) method was used to test the ability of the constructed network to predict the single held out sample from each iteration with a maximum predictive accuracy of 87% and an average predictive accuracy of 82% over the range of proteins chosen for its construction.

The invention discloses a three-way-decision-based liver tumor CT image classification method. A classifier is trained; image preprocessing and feature extraction are carried out on a marked liver CT image training sample to form a feature vector; rule extraction is carried out by using an attribute reduction method to form a knowledge base, thereby providing a basis for follow-up case classification diagnoses. T-be-classified cases are processed image pretreatment to extract liver regions, hepatic vessels, and liver tumors; 14 case features are calculated; the case feature values are inputted into a three-way-decision-based classifier; and then cases are classified into three types: a benign tumor, a malignant tumor, and an uncertain tumor. Therefore, a doctor can make different therapeutic regimens for different tumor types.

The invention discloses a cell membrane tumor vaccine and a preparation method and an application thereof. For the first time, exogenous tumor antigens and adoptive cells are not used, a cell fusion technology is used to fuse dendritic cells and tumor cells, and after culture, the whole tumor antigen and costimulatory molecules are expressed on the cell membrane of the fused cells. A nano cell membrane vaccine prepared by coating the nanoparticle with the cell membrane subjected to peeling of the fused cell can directly activate the T cell like the antigen presenting cell, can also be recognized by the dendritic cell, processed and presented to the T cell, and indirectly activates the T cell. Two T cells are combined for activation of pathways, which can cause the strong anti-tumor immuneresponse. A cell membrane tumor vaccine strategy that mimics the tumor cells and the antigen presenting cells enables the development of the vaccines against a variety of tumor types, and has good biocompatibility and system safety. Therefore, the cell membrane vaccine is very suitable for the field of tumor vaccines.

A therapeutic composition for treating a proliferative disorder includes a VEGF antagonist and β-glucan. VEGF is overexpressed in some tumor types. The efficacy of treatment with VEGF antagonists capable of activating complement in combination with β-glucan is significantly increased.

Disclosed are biomarkers, methods and assay systems for the identification of cancer patients who are predicted to respond, or not respond to the therapeutic administration of radiation therapy to treat cancer. Thus, the invention provides a diagnostic paradigm to select cancer patients who will benefit from radiation therapy. In particular, the invention provides a novel 41-gene biomarker model associated with clinical outcome following radiotherapy across multiple histological tumor types, including the biomarker Cyclophilin B (PPIB).

Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy.

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity.

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.

GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.

A method is disclosed for assaying the sensitivity of neoplastic tissue to therapeutic agents, and in particular, for the quantification of pro-apoptotic marker mRNA expression in cells obtained from thinly-sliced living tumor tissue in such methods. The method may comprise ascertaining a particular apoptosis marker mRNA for an individual tumor or tumor type as well as exposure of thin-sliced live cancer tissues from the individual tumor to candidate chemotherapeutic drug regimes in vitro, followed by an assessment of the level of the marker mRNA in the tissue.

The present invention provides novel compounds of the formula (I) and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

The invention provides a methylation tumor marker STAMP-EP6 and application thereof, and belongs to the field of disease diagnosis markers. The invention provides application of the methylation tumormarker STAMP-EP6 in preparing a tumor diagnosis reagent. The tumor marker STAMP-EP6 is highly methylated in all tumor types, and is lowly methylated in corresponding normal tissue, and has high sensibility and specificity, and a primer for detecting the STAMP-EP6 can be used for preparing a tumor diagnosis kit.

The invention discloses a cancer subtyping method and a device based on RNA targeted sequencing and machine learning. According to the method, through RNA targeted sequencing technology, a target genearea is concentrated efficiently. Through steps of inverse transcription, database establishing and sequencing, second-generation sequencing data of the target area are obtained. Furthermore a randomforest algorithm is used for training on a TCGA dataset for obtaining a tumor typing predicting model, thereby accurately performing cancer subtyping. The method according to the invention can obtaina model for realizing lung cancer and renal cell carcinoma typing with high accuracy. The method according to the invention can reduce typing cost. Furthermore the typing speed, precision and the typing result accuracy are better than that of a traditional method.

The invention relates to the technical field of auxiliary instruments, in particular to a middle and distal tibia tumor type prosthesis and a preparation device and method thereof. The preparation device comprises an image acquisition system for collecting tibia image data and a 3D printing system for printing a prosthesis model. The bilateral tibiofibula CT scanning is performed before an operation, the 3D tibiofibula of the affected side is reconstructed by reverse software, and the undercut range is expected corresponding to the tibia malignant tumor to make a middle and distal tibia tumortype prosthesis image to obtain intuitive understanding of the diseased tibia. The intraoperative prosthesis handle portion and the ankle mortise are compressed tightly with the host proximal tibia and the proximal talus osteotomy side, and fixed with multiple screws to complete the initial stabilization of the connection between two ends of the prosthesis and the host bone tissue. The porous surface of the proximal end of the prosthesis handle portion and the metal ankle mortise (a cavity at the ankle bone end) can promote the bone ingrowth, and the long-term postoperative stability is strengthened.

The invention discloses a double-layer micro-fluidic chip for capturing circulating tumor cells, and belongs to the technical field of micro-fluidic. The double-layer micro-fluidic chip comprises an upper-layer chip and a lower-layer chip which are correspondingly arranged up and down and are communicated with each other, and micro-column arrays are arranged in the upper-layer chip and the lower-layer chip so as to capture the tumor cells for multiple times; and a bowl-shaped structure is also arranged in the lower-layer chip to gather the tumor cells, so that signals are enhanced when characteristic spectrums of enriched CTCs are detected by laser, and the tumor type and gene protein spectral characteristics of a tumor patient can be obtained. According to the double-layer micro-fluidic chip, the defect of low tumor cell capture rate in the prior art is overcome, the structural design is ingenious, capture methods of circulating the tumor cells can be combined and selected according to requirements, the capture rate of CTCs is increased, and missing of individual tumor cells is avoided.

The invention provides a methylation tumor marker STAMP-EP5 and application thereof and belongs to the field of disease diagnosis markers. The invention provides the application of the methylation tumor marker STAMP-EP5 to preparation of tumor diagnosis reagents. The tumor marker STAMP-EP5 provided by the invention shows high methylation in all tumor types and low methylation in corresponding normal tissues, and has extremely high sensitivity and specificity; a primer for detecting the STAMP-EP5 can be used for preparing a tumor diagnosis kit.

The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

Disclosed are novel nucleic acid and peptide compositions comprising methythioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and idenification tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.

The invention discloses application of a MAPK-ERK1 / 2 signal channel inhibitor to the preparation of double-minute medicine for removing or inhibiting tumor cells and belongs to the technical field of tumor biological treatment. By aiming at the poor tumor treatment effect in the prior art, a target biological treatment strategy of tumors containing double minutes is further provided, the fact that double minutes in malignant cells and the ERK1 / 2 protein kinase activity have the close relationship obtained through research is used as the theoretical basis, and the application disclosed by the invention is specially provided by aiming at the ERK1 / 2 protein kinase continuous phosphorylation double-minute tumor type caused by the MAPK-ERK1 / 2 signal transduction channel abnormity. The method disclosed by the invention has the advantages that the tumor treatment specificity is improved, the existing treatment scheme is improved, and on the other hand, the invention also provides a strategy for double-minute targeting treatment.